Co PSMA Prostate Imaging Data Presented at EAU Congress

Why It Matters

The superior detection capability of 64Cu‑SAR‑bisPSMA could reshape imaging standards for biochemical recurrence, accelerating personalized salvage therapy and supporting FDA approval for a high‑need patient segment.

Key Takeaways

• 64Cu‑SAR‑bisPSMA detected 2.6× more lesions
• Positive scans rose from 36% to 78%
• Management changed in 44% of participants
• True‑positive rate 71% vs 29% for 68Ga
• Phase III AMPLIFY trial enrollment completed

Pulse Analysis

Prostate‑specific membrane antigen (PSMA) PET imaging has become a cornerstone for locating recurrent disease after radical prostatectomy, yet conventional tracers like 68Ga‑PSMA‑11 struggle with low PSA values. The emergence of copper‑64 labeled agents, particularly 64Cu‑SAR‑bisPSMA, offers longer half‑life and higher tumor uptake, enabling delayed imaging that captures lesions missed on earlier scans. This technical advantage aligns with a broader industry shift toward isotopes that balance resolution, logistics, and patient convenience.

The Co‑PSMA investigator‑initiated trial, presented at the European Association of Urology meeting, provided head‑to‑head evidence in 50 men with median PSA 0.43 ng/mL. The 24‑hour 64Cu‑SAR‑bisPSMA scan revealed 63 lesions across participants, compared with just 24 for 68Ga‑PSMA‑11, translating to a mean per‑patient lesion count of 1.26 versus 0.48 (p < 0.0001). Beyond raw detection, the new tracer shifted clinical decisions in 22 patients, underscoring its potential to guide targeted salvage radiotherapy or surgery when biochemical failure looms.

These findings reinforce Clarity Pharmaceuticals’ regulatory strategy, as the data complement earlier COBRA results and feed into the pivotal Phase III AMPLIFY study, which recently met enrollment targets. With three Fast Track Designations and a pending submission to the U.S. FDA, 64Cu‑SAR‑bisPSMA is positioned to become the preferred PSMA PET agent for biochemical recurrence. Adoption could drive earlier, more precise interventions, improve outcomes, and generate a sizable market for a radiopharmaceutical that addresses an unmet diagnostic gap.